Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ metabolism
Female
Humans
Intestinal Neoplasms
/ diagnosis
Intracellular Signaling Peptides and Proteins
/ metabolism
Male
Membrane Proteins
/ metabolism
Middle Aged
Neuroendocrine Tumors
/ diagnosis
Pancreatic Neoplasms
/ diagnosis
Retrospective Studies
Stomach Neoplasms
/ diagnosis
DLL3
GEP-NEN
NEC
Prognostic marker
Journal
Endocrine pathology
ISSN: 1559-0097
Titre abrégé: Endocr Pathol
Pays: United States
ID NLM: 9009288
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
accepted:
09
12
2020
pubmed:
8
1
2021
medline:
23
11
2021
entrez:
7
1
2021
Statut:
ppublish
Résumé
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a rare and heterogeneous subgroup of tumors with a challenging management because of their extremely variable biological and clinical behaviors. Due to their different prognosis, there is an urgent need to identify molecular markers which would enable to discriminate between grade 3 neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), despite both being diagnosed mainly on the basis of proliferation index and cell differentiation. DLL3, a negative Notch regulator, is a promising molecular target highly expressed in several tumors with neuroendocrine features. We conducted a retrospective analysis of DLL3, RB1, and PD-L1 expression by immunohistochemistry (IHC), in formalin-fixed, paraffin-embedded (FFPE) samples from 47 patients with GEP-NENs. Then, we correlated the results with patients' clinical features and outcome. The absence of DLL3 expression in 5 well-differentiated GEP-NETs with high-grade features (G3 NET), and the presence of DLL3 in 76.9% of poorly-differentiated NECs (G3 NEC), highlights DLL3 expression as a marker of G3 NECs (p = 0.007). DLL3 expression was correlated with RB1-loss (p < 0.001), negative
Identifiants
pubmed: 33409812
doi: 10.1007/s12022-020-09657-8
pii: 10.1007/s12022-020-09657-8
doi:
Substances chimiques
Biomarkers, Tumor
0
DLL3 protein, human
0
Intracellular Signaling Peptides and Proteins
0
Membrane Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
309-317Références
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker R V., Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9(1):61-72.
pubmed: 18177818
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3(10):1335-1342.
pubmed: 28448665
pmcid: 5824320
Klöppel G, Couvelard A, Hruban RH, Klimstra DS, Komminoth P, Osamura RY, Perren A, Rindi G (2017) WHO classification of neoplasms of the neuroendocrine pancreas. In: Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) WHO classification of tumours of endocrine organs. IARC Press, Lyon.
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA (2020) The 2019 WHO classification of tumours of the digestive system. Histopathology 76(2):182-188.
pubmed: 31433515
Zatelli MC, Guadagno E, Messina E, Lo Calzo F, Faggiano A, Colao A, Albertelli M, Bianchi A, Circelli L, De Cicco F et al (2018) Open issues on G3 neuroendocrine neoplasms: Back to the future. Endocr Relat Cancer 25(6):R375-R384.
pubmed: 29669844
Kawasaki K, Fujii M, Sato T (2018) Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models. Dis Model Mech 11(2).
Oronsky B, Ma PC, Morgensztern D, Carter CA (2017) Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia 19(12):991-1002.
pubmed: 29091800
pmcid: 5678742
Kwekkeboom DJ, Krenning EP (2016) Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am 30(1):179-91.
pubmed: 26614376
Uri I, Grozinsky-Glasberg S (2018) Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diabetes Endocrinol 4:16.
pubmed: 30009041
pmcid: 6042326
Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA (2019) Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs 79(1):21-42.
pubmed: 30560479
Tsoli M, Chatzellis E, Koumarianou A, Kolomodi D, Kaltsas G (2019) Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab 10:2042018818804698.
pubmed: 30800264
Walter T, Brixi-Benmansour H, Lombard-Bohas C, Cadiot G (2012) New treatment strategies in advanced neuroendocrine tumours. Dig Liver Dis 44(2):95-105.
pubmed: 21983252
Bongiovanni A, Riva N, Ricci M, Liverani C, La Manna F, De Vita A, Foca F, Mercatali L, Severi S, Amadori D, Ibrahim T (2015) First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma. Onco Targets Ther 8:3613-9.
pubmed: 26664145
pmcid: 4671803
Nigri G, Petrucciani N, Debs T, Mangogna LM, Crovetto A, Moschetta G, Persechino R, Aurello P, Ramacciato G (2018) Treatment options for PNET liver metastases: A systematic review. World J Surg Oncol 16(1):142.
pubmed: 30007406
pmcid: 6046097
Garcia-Carbonero R, Sorbye H, Baudin E et al (2016) ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 103(2):186-94.
pubmed: 26731334
Kim JY, Hong SM, Ro JY. (2017) Recent updates on grading and classification of neuroendocrine tumors.Ann Diagn Pathol. 11–16.
Tang KH, Basturk O, Sue JJ, Klimstra DS (2016) A Practical Approach to the Classification of WHO Grade 3 (G3) Well differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the Pancreas Am J Surg Pathol.Am J Surg Pathol. 40(9): 1192–1202.
Aster JC, Pear WS, Blacklow SC (2017) The Varied Roles of Notch in Cancer. Annu Rev Pathol 12:245-275.
pubmed: 27959635
Kunnimalaiyaan M, Chen H (2007) Tumor Suppressor Role of Notch‐1 Signaling in Neuroendocrine Tumors. Oncologist 12(5):535-42.
pubmed: 17522241
Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M, Hsiao EC, Schuebel KE, Borges MW, Jin N, Collins BJ, Nelkin BD, Chen H, Ball DW (2005) Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab 90(7):4350-6.
pubmed: 15870121
Kunnimalaiyaan M, Yan S, Wong F, Zhang YW, Chen H, Skogseid B, Dackiw APB, Kebebew E (2005) Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery 138(6):1137-42.
pubmed: 16360401
George J, Walter V, Peifer M et al (2018) Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun 9(1):1048.
pubmed: 29535388
pmcid: 5849599
Zou B, Zhou XL, Lai SQ, Liu JC (2018) Notch signaling and non-small cell lung cancer. Oncol Lett 15(3):3415-3421.
pubmed: 29467866
pmcid: 5796339
Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L, Pan H, Motanagh S, Hess J, Donoghue AJ, Sboner A, Wang Y, Dittamore R, Rickman D, Nanus DM, Tagawa ST, Elemento O, Mosquera JM, Saunders L, Beltran H (2019) Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med 11(484).
Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, Spadazzi C, Miserocchi G, Recine F, Riva N, Nicolini S, Severi S, Martinelli G, Ibrahim T (2018) Grading of neuroendocrine carcinomas: Correlation of 68 Ga-PET/CT scan with tissue biomarkers. Dis Markers 2018:6878409.
pubmed: 30627226
pmcid: 6304840
Segelov E, Chan D, Lawrence B, Pavlakis N, Kennecke HF, Jackson C, Law C, Singh S (2017) Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration. J Glob Oncol 3(4):380-388.
pubmed: 28831446
Perren A, Couvelard A, Scoazec JY et al (2017) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification. Neuroendocrinology 105(3):196-200.
pubmed: 28190015
Saunders LR, Bankovich AJ, Anderson WC et al (2015) A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 7(302):302ra136.
Tanaka K, Isse K, Fujihira T, Takenoyama M, Saunders L, Bheddah S, Nakanishi Y, Okamoto I (2018) Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer 115:116-120.
pubmed: 29290251
Thoma C (2019) Targeting DLL3 in neuroendocrine prostate cancer. Nat Rev Urol 16(6):330.
pubmed: 31040438
Alcala N, Leblay N, Gabriel AAG et al (2019) Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nat Commun 10(1):3407.
pubmed: 31431620
pmcid: 6702229
Sorbye H, Welin S, Langer SW, et al. (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol 24(1):152-60.
pubmed: 22967994
Sorbye H, Baudin E, Perren A (2018) The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond. Endocrinol Metab Clin North Am 47(3):683-698.
pubmed: 30098724
Sigel CS, Krauss Silva VW, Reid MD, et al. Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study. Cancer Cytopathol. 2018;126(1):44-53.
pubmed: 29044913
Jiao Y, Shi C, Edil BH et al (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021):1199‐1203.
pubmed: 21252315
pmcid: 3144496
Chan CS, Laddha SV, Lewis PW et al (2018) ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun (1):4158.
Singhi AD, Klimstra DS. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. Histopathology. 2018;72(1):168-177.
pubmed: 29239037
Tang LH, Untch BR, Reidy DL, et al. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res. 2016;22(4):1011-1017.
pubmed: 26482044
Ito T, Matsuo A, Hassan WA (2016) Notch signaling and Tp53/RB1 pathway in pulmonary neuroendocrine tumorigenesis. Translational Cancer Research 5(2):213-219.
Meder L, König K, Ozretić L, Schultheis AM, Ueckeroth F, Ade CP, Albus K, Boehm D, Rommerscheidt-Fuss U, Florin A, Buhl T, Hartmann W, Wolf J, Merkelbach-Bruse S, Eilers M, Perner S, Heukamp LC, Buettner R (2016) NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int J Cancer 138(4):927-38.
pubmed: 26340530
Rinke A, Gress TM (2017) Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers. Digestion 95(2):109-114.
pubmed: 28161703
Rudin CM, Pietanza MC, Bauer TM et al (2017) Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 18(1):42-51.
pubmed: 27932068
Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, Glisson BS, Farago AF, Dowlati A, Rudin CM, Le Moulec S, Lally S, Yalamanchili S, Wolf J, Govindan R, Carbone DP (2019) Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: Results from the phase II TrINITY study. Clin Cancer Res 25(23):6958-6966.
pubmed: 31506387
pmcid: 7105795
Owen DH, Giffin MJ, Bailis JM, Smit MAD, Carbone DP, He K (2019) DLL3: An emerging target in small cell lung cancer. J Hematol Oncol 12(1):61.
pubmed: 31215500
pmcid: 6582566
Tang J, Shalabi A, Hubbard-Lucey VM (2018) Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol 29(1):84-91.
pubmed: 29228097
Cunha LL, Marcello MA, Rocha-Santos V, Ward LS (2017) Immunotherapy against endocrine malignancies: Immune checkpoint inhibitors lead the way. Endocr Relat Cancer 24(12):T261-T281.
pubmed: 28893836
Cavalieri S, Rivoltini L, Bergamini C, Locati LD, Licitra L, Bossi P (2018) Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. Cancer Treat Rev 65:78-86.
pubmed: 29574334
Meléndez B, Van Campenhout C, Rorive S, Remmelink M, Salmon I, D’Haene N (2018) Methods of measurement for tumor mutational burden in tumor tissue. Transl Lung Cancer Res 7(6):661-667.
pubmed: 30505710
pmcid: 6249625
Christofi T, Baritaki S, Falzone L, Libra M, Zaravinos A (2019) Current perspectives in cancer immunotherapy. Cancers (Basel) 11(10).
Cavalcanti E, Armentano R, Valentini AM, Chieppa M, Caruso ML (2017) Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death Dis 8(8):e3004.
pubmed: 28837143
pmcid: 5596583
Milione M, Miceli R, Barretta F, Pellegrinelli A, Spaggiari P, Tagliabue G, Centonze G, Paolino C, Mangogna A, Kankava K, Pusceddu S, Giacomelli L, Corti A, Cotsoglou C, Mazzaferro V, Sozzi G, de Braud F, Pruneri G, Anichini A (2019) Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms. J Pathol Clin Res 5(4):217-226.
pubmed: 31136102
pmcid: 6817832